The Honest Company Sets Anticipated IPO Range socaltech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from socaltech.com Daily Mail and Mail on Sunday newspapers.
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
News provided by
Share this article
STOCKHOLM, April 26, 2021 /PRNewswire/
The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on Thursday 27 May 2021.
In order to mitigate the spread of Covid-19, the Board of Directors has decided that the annual general meeting will be conducted by advance voting only, without physical presence of shareholders, proxies and third parties.
Calliditas Therapeutics welcomes all shareholders to exercise their voting rights at this annual general meeting through advance voting on the basis of temporary statutory rules, according to the procedure set out below. Information on the resolutions passed at the annual general meeting will be published on 27 May 2021, as soon as the result of the voting has been finally confirmed.
Utah Business
On April 20, 2021, Recursion Pharmaceuticals, Inc. of Salt Lake City announced the closing of its initial public offering of 27,878,787 shares of its Class A common stock at a price to the public at $18.00 per share, a price at the top end of its expected pricing range. Recursion shares began trading on the Nasdaq Global Select Market on Friday, April 16, 2021 under the symbol “RXRX.” That day the share price surged, rising as much as 82 percent. In the past week Recursion shares have fluctuated between $25 and $35 per share, well above the $18 debut price. The offering has generated over $460 million for the company net of expenses.
Notice of annual general meeting of Calliditas Therapeutics AB (publ) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Treace Medical Concepts Announces Pricing of Upsized Initial Public Offering Treace Medical Concepts, Inc. Ponte Vendra Beach, Florida, UNITED STATES
PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the pricing of its upsized initial public offering of an aggregate of 11,250,000 shares of its common stock, 6,250,000 of which are being sold by Treace and 5,000,000 of which are being sold by certain selling stockholders, at a public offering price of $17.00 per share. The gross proceeds from the offering to Treace are expected to be approximately $106.3 million before deducting underwriting discounts and commissions and other offering expenses payable by Treace. Treace will not receive any proceeds from the sale of shares by the s